Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma

CONCLUSIONS: In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.PMID:38478923 | DOI:10.1093/oncolo/oyae037

Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Andrew C Johns Matthew T Campbell Mamie Gao Andrew W Hahn Zita Lim Emily Wang Jianjun Gao Amishi Y Shah Pavlos Msaouel Nizar M Tannir Source Type: research